Pemetrexed: A multitargeted antifolate agent with promising activity in solid tumors

Annals of Oncology

Volumn 11, Issue 10, 2000, Pages 1335-1341

  Adjei, A A ^a  

^a MAYO CLINIC   (United States)

Author keywords

Multitargeted antifolate; Solid tumors; Thymidylate synthase

Indexed keywords

CARBOPLATIN; CISPLATIN; DIHYDROFOLATE REDUCTASE; DOCETAXEL; FLUOROURACIL; FOLIC ACID; FOLIC ACID ANTAGONIST; GEMCITABINE; IRINOTECAN; LOMETREXOL; METHOTREXATE; OXALIPLATIN; PACLITAXEL; PEMETREXED; PHOSPHORIBOSYLGLYCINAMIDE FORMYLTRANSFERASE; RALTITREXED; THYMIDYLATE SYNTHASE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BLADDER CARCINOMA; BONE MARROW SUPPRESSION; BREAST CARCINOMA; CLINICAL TRIAL; COLON CARCINOMA; DRUG SAFETY; ENZYME INHIBITION; HUMAN; LIVER TOXICITY; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; PANCREAS CARCINOMA; PRIORITY JOURNAL; SKIN TOXICITY; SOLID TUMOR; UTERINE CERVIX CARCINOMA;

ANTINEOPLASTIC AGENTS; FOLIC ACID ANTAGONISTS; GLUTAMATES; GUANINE; HUMANS; NEOPLASMS;

EID: 0033758532     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1008379101017     Document Type: Article

References (44)

1. A phase I trial of the farnesyl transferase inhibitor SCH66336: Evidence for biological and clinical activity
2. Phase I and pharmacologic study of the tyrosine kinase inhibitor SU101 in patients with advanced solid tumors
3. ZD1839, an oral epidermal growth factor receptor tyrosine kinase inhibitor: First phase I, pharmacokinetic results in patients
4. LY231514, a novel pyrrolopyrimidine antifolate that inhibits thymidylate synthase (TS)
5. Antimetabolites
6. LY231514 and its polyglutamates exhibit potent inhibition against both human dihydrofolate reductase (DHFR) and thymidylate synthase (TS): Multiple folate enzyme inhibition
7. Fluorinated pyrimidines
8. Comparative antitumor activity of the multitargeted antifolate LY231514 and the thymidylate synthase inhibitor ZD1694
9. Role of thymidylate synthase in the antitumor activity of the multitargeted antifolate, LY231514
10. Polyglutamation of methotrexate, Is methotrexate a prodrug?
11. Preclinical pharmacology studies and the clinical development of a novel multitargeted antifolate, MTA (LY231514)
12. An update on thymidylate synthase inhibitors
13. Activity of LY231514 against several enzymes in the folate-dependent pathways
14. LY231514, a pyrrolo(2,3-d)pyrimidine-based antifolate that inhibits multiple folate-requiring enzymes
15. Metabolism and disposition of the antifolate LY231514 in mice and dogs
16. Phase I and pharmacokinetic study of LY231514, the multitargeted antifolate, administered by daily x 5 q 21 schedule
17. Initial phase I evaluation of the novel thymidylate synthase inhibitor LY231514, using the modified continual assessment method for dose escalation
18. A phase I evaluation of LY231514, a novel multi-targeted antifolate, administered every 21 days
19. Multitargeted antifolate (LY231514) activity in patients with advanced colorectal cancer - Results of a phase II study
20. Phase II study of first-line LY231514 (multi-targeted antifolate) in patients with locally advanced or metastatic colorectal cancer: An NCIC Clinical Trials Group study
21. A phase II trial of MTA (multiple targeted antifolate, LY231514) in patients with 5-FU and irinotecan-refractory colorectal cancer
22. Phase II study of the multi-targeted antifolate LY231514 (ALIMTA, MTA, pemetrexed disodium) in patients with advanced pancreatic cancer
23. Multitargeted antifolate LY231514 as first-line chemotherapy for patients with advanced non-small-cell lung cancer: A phase II study
24. Phase II study of LY231514 in patients with advanced non-small-cell lung cancer (NSCLC)
25. Phase II trial of MTA (LY231514) in patients (PTS) with non-small-cell lung cancer (NSCLC) who relapsed after previous platinum or non-platinum chemotherapy
26. Phase II study of MTA (LY231514) in patients (pts) with locally recurrent or metastatic breast cancer (LR/MBC)
27. MTA (multitargeted antifolate, LY231514) in metastatic breast cancer patients (pts) with prior anthracycline exposure: An European phase II study
28. Clinical studies with MTA
29. A phase II study of the multi-targeted antifolate, MTA (LY231514), in patients with advanced transitional cell carcinoma (TCC) of the bladder
30. MTA (LY231514) in advanced carcinoma of the cervix
31. An overview of folate metabolism: Features relevant to the action and toxicities of antifolate anticancer agents
32. Metabolic abnormalities in cobalamin (vitamin B12) and folate deficiency
33. Laboratory diagnosis of vitamin B12 and folate deficiency: A guide for the primary care physician
34. The B vitamins and vitamin C in human nutrition. I. General considerations and 'obligatory' B vitamins
35. The effect of a subnormal vitamin B-6 status on homocysteine metabolism
36. Elevation of serum cystathionine levels in patients with cobalamin and folate deficiency
37. MTA (LY231514): Relationship of vitamin metabolite profile, drug exposure, and other patient characteristics to toxicity
38. A phase I and pharmacokinetic (PK) study of the multitargeted antifolate (MTA, LY231514) with folic acid
39. A phase I and pharmacologic study of sequences of gemcitabine and the multitargeted antifolate agent (MTA) in patients with advanced solid tumors
40. Cell cycle modulation by a multitargeted antifolate, LY231514, increases the cytotoxicity and antitumor activity of gemcitabine in HT29 colon carcinoma
41. Clinical and pharmacokinetic phase I study of multitargeted antifolate (LY231514) in combination with cisplatin
42. Phase I and pharmacokinetic study (PK) of the multitargeted antifolate LY231514 (MTA) in combination with irinotecan (CPT-11)
43. A phase I dose escalation study of the multitargeted antifolate, LY231514 (MTA) in combination with 5-fluorouracil (5-FU): Dependence of toxicity on schedule of 5-FU administration
44. MTA (LY231514) demonstrates clinical activity against malignant mesothelioma in a phase I combination trial with carboplatin